Unternehmensübersicht
Firefly Neuroscience, Inc. operates as a specialized entity within the technology sector, specifically focusing on the software application industry to deliver neuroscientific solutions aimed at enhancing brain health outcomes for patients suffering from mental illnesses and neurological disorders. The company's core offering includes Brain Network Analytics, a proprietary software suite dedicated to diagnostic applications in the field of neuroscience. With a market capitalization of $26.71M, Firefly Neuroscience represents a small-cap technology firm, indicating a business that is still in a developmental or early commercialization phase rather than a mature, large-scale enterprise. The annual revenue recorded over the trailing twelve months stands at $1.14M, while the employee count is currently listed as N/A, suggesting a lean organizational structure typical of early-stage biotech or medtech ventures where capital efficiency is prioritized over headcount expansion. These financial metrics collectively portray a company that is generating minimal top-line income relative to its valuation, highlighting the high-risk, high-potential nature often associated with firms developing complex artificial intelligence and medical technology solutions.
Finanzielle Gesundheit
Over the trailing twelve months, Firefly Neuroscience reported a revenue of $1.14M, yet it recorded a net income of $-24,531,000 and an EBITDA of $-8,464,000, revealing a profound disconnect between top-line generation and bottom-line profitability driven by significant operating expenses. The disparity between the $1.14M revenue and the substantial net loss indicates a cost structure dominated by research and development expenditures, which are necessary for advancing neuroscientific algorithms but currently suppress immediate earnings. The company generated a free cash flow of $-6,578,250, a figure that underscores a negative cash burn rate and implies limited financial flexibility for sustaining operations without external capital injections or future equity issuances. In terms of profitability margins, the gross margin stands at 56.5%, demonstrating that the company retains a healthy portion of revenue after direct costs, whereas the operating margin of -583.0% and the profit margin of 0.0% reflect severe operational inefficiencies or high fixed costs relative to the current sales volume. Regarding liquidity and leverage, Firefly Neuroscience holds $2.75M in cash against zero debt, resulting in a debt-to-equity ratio that is N/A, which suggests a conservative balance sheet structure free from interest-bearing liabilities. The current ratio is reported at 1.43, indicating that the company possesses sufficient current assets to cover its short-term obligations, though the margin of safety is not particularly robust given the ongoing cash burn. Furthermore, the return on equity is -547.6% and the return on assets is -70.9%, metrics that clearly demonstrate that management has not yet been effective at generating positive returns on the capital base, a common characteristic of pre-profitability technology firms.
Bewertungsanalyse
The trailing P/E ratio is N/A due to the negative earnings, and the forward P/E is also N/A, implying that traditional earnings-based valuation methods are currently inapplicable and that the market is pricing the stock based on future potential rather than current profitability. The price-to-book ratio is 3.11, indicating that the market values the company at a significant premium of over three times its net asset value, likely reflecting high expectations for the future commercial success of its artificial intelligence and neuroscientific platform. Additionally, the price-to-sales ratio is 23.39 and the EV/EBITDA stands at -2.65, suggesting that investors are willing to pay more than twenty-three times the annual sales figure, which is an aggressive valuation metric typical for high-growth biotech or software startups with unproven revenue models. The stock's price volatility is framed by a 52-week high of $4.51 and a 52-week low of $0.62, meaning the current price sits within a wide trading range that reflects the inherent uncertainty and speculative nature of the asset class. Although the beta value is N/A, the wide spread between the high and low prices indicates substantial price instability relative to broader market benchmarks, driven by the binary outcomes typical of clinical trial results or product approvals in the medical technology sector.
Growth & Income
Firefly Neuroscience demonstrated a revenue growth rate of 677.4% year-over-year, while the earnings growth rate is N/A due to the company's persistent losses, illustrating that top-line expansion is currently occurring without a corresponding improvement in profitability. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning that the firm retains all of its limited earnings to fund research, development, and operational scaling rather than distributing cash to shareholders. This reinvestment strategy is standard for loss-making technology companies, as they prioritize long-term asset accumulation and market penetration over immediate income generation for investors. Overall, the growth and income profile of Firefly Neuroscience is characterized by explosive top-line expansion paired with deep operational losses and no current income distribution, positioning the stock as a speculative play on the future success of its diagnostic software solutions rather than a stable income investment.